Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia

Jean-Damien Ricard, Jonathan Messika
European Respiratory Journal 2015 46: 876-877; DOI: 10.1183/09031936.00048715
Jean-Damien Ricard
1AP-HP, Service de Réanimation Médico-Chirurgicale, Hôpital Louis Mourier, Colombes, France
2INSERM, IAME, 1137, Paris, France
3Univ Paris Diderot, IAME, 1137, Sorbonne Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: jean-damien.ricard@lmr.aphp.fr
Jonathan Messika
1AP-HP, Service de Réanimation Médico-Chirurgicale, Hôpital Louis Mourier, Colombes, France
2INSERM, IAME, 1137, Paris, France
3Univ Paris Diderot, IAME, 1137, Sorbonne Paris Cité, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Due to the risk of delaying antibiotherapy, NSAID should not be given if an ongoing infection hasn't been ruled out http://ow.ly/LCQMZ

From the authors:

We read with attention the letter by E. Crawford and co-workers and thank them for their interests in our work.

Our retrospective study [1] found that among patients admitted to our intensive care unit (ICU) with pneumococcal community-acquired pneumonia (CAP), we were able to distinguish two distinct populations with respect to exposure to Nonsteroidal anti-inflammatory drugs (NSAIDs). The group of patients who had taken NSAIDs was, surprisingly, much younger (on average 20 years younger) and in a healthier condition than those who had not. Counterintuitively, the much younger and healthier patient group required ICU and organ failure support in a similar manner to those who were sicker and older. We raised the hypothesis that exposure to NSAIDs may have contributed to this situation, possibly by blunting signs and delaying antibiotic prescription. Because our results are in line with other data on the danger of NSAIDs in other infectious settings [2], such as soft tissue infections [3], our conclusion was one of caution regarding the use of NSAID in the context of an infection in progress.

E. Crawford and co-workers argue that our data do not support our conclusion, and that NSAIDs might well have been given because pleural effusion was already present.

They erroneously state that there was no delay in antibiotic prescription. On the contrary, we found that patients exposed to NSAIDs received antibiotics 4.5 days after initial medical consultation, whereas those who did not receive NSAIDs received antibiotics sooner, 2.5 days after initial consultation. Interestingly, time from onset of symptoms to initial consultation was identical in the two groups, suggesting that the degree of severity of symptoms and overall presentation were similar at the start. In an ongoing infectious process, this delay can have serious consequences and may well explain, contrary to E. Crawford and co-workers' hypothesis, the greater pleural involvement in the exposed patients, although we agree our results are not definite proof of NSAIDs' responsibility. We also acknowledge the retrospective nature of our study and its limits.

Nonetheless, NSAIDs are not the innocuous medication E. Crawford and co-workers suggest they are i.e. that they can be widely prescribed in the community. Excess deaths associated with NSAIDs exceed sixteen thousand patients a year in the USA [4] and costs associated with side effects from NSAIDs reaches €59 million in the Netherlands annually [5].

We are not “extrapolating data from intensive care populations to guide treatment of all patients in the wider community”, since the data we gathered came from the community!

And guiding treatment is precisely a key issue! Surprisingly (or not…), NSAIDs do not appear in the USA [6], European [7] or French [8] guidelines on management of CAP and lower respiratory tract infections. They solely appear in the British Thoracic Society guidelines, and only after paracetamol “for symptomatic treatment of pleuritic chest pain of pneumonia treated in the community” [9]. Importantly, paracetamol is recommended with a weak level of evidence (D) but NSAIDs appear without any evidence whatsoever. In addition, use of NSAIDs do not appear in the BTS guidelines for the management of pleural infection [10]. Hence, there is no data to support the use of NSAIDs as an adjunct therapy for CAP.

Diagnosing CAP in the community is not an easy task, especially in young adults. Our concern is that precisely because they are younger and healthier with fewer comorbidities, they receive fewer (or less promptly) antibiotics. Alleviating pain is a necessary and laudable goal but, to date, no study has demonstrated the superiority of NSAIDs over paracetamol in pneumonia-associated pleuritic chest pain, whereas there is ample evidence demonstrating the detrimental consequence of delaying antibiotherapy.

Caution warrants that general practitioners should avoid NSAIDs in patients with clinical signs suggestive of pneumonia. One should be wary of over interpreting inexistent data.

Footnotes

  • Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

  • Received March 25, 2015.
  • Accepted April 5, 2015.
  • Copyright ©ERS 2015

References

  1. ↵
    1. Messika J,
    2. Sztrymf B,
    3. Bertrand F, et al.
    Risks of nonsteroidal antiinflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients. J Crit Care 2014; 29: 733–738.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Leroy S,
    2. Marc E,
    3. Bavoux F, et al.
    Hospitalization for severe bacterial infections in children after exposure to NSAIDs: a prospective adverse drug reaction reporting study. Clin Drug Investig 2010; 30: 179–185.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Souyri C,
    2. Olivier P,
    3. Grolleau S, et al.
    Severe necrotizing soft-tissue infections and nonsteroidal anti-inflammatory drugs. Clin Exp Dermatol 2008; 33: 249–255.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Wolfe MM,
    2. Lichtenstein DR,
    3. Singh G
    . Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888–1899.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Herings RM,
    2. Klungel OH
    . An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001; 19: 655–665.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Mandell LA,
    2. Wunderink RG,
    3. Anzueto A, et al.
    Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: Suppl. 2, S27–S72.
    OpenUrlFREE Full Text
  7. ↵
    1. Woodhead M,
    2. Blasi F,
    3. Ewig S, et al.
    Guidelines for the management of adult lower respiratory tract infections--full version. Clin Microbiol Infect 2011; 17, Suppl. 6, E1–59.
    OpenUrlCrossRefPubMed
  8. ↵
    Société de Pathologie Infectieuse de Langue Française. XVe Conférence de consensus en therapeutique anti- infectieuse. Prise en accusation des infections des Voies respiratoires bassesde l' adulte immunocompétent. [15th consensus conference about management of lower respiratory tract infections in immunocompetent adult]. Med Mal Infect 2006; 36: 235–244.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Lim WS,
    2. Baudouin SV,
    3. George RC, et al.
    BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64: Suppl. 3, iii1–ii55.
    OpenUrlFREE Full Text
  10. ↵
    1. Davies HE,
    2. Davies RJ,
    3. Davies CW, et al.
    Management of pleural infection in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax 2010; 65: Suppl. 2, ii41–ii53.
    OpenUrlFREE Full Text
View Abstract
Previous
Back to top
View this article with LENS
Vol 46 Issue 3 Table of Contents
European Respiratory Journal: 46 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia
Jean-Damien Ricard, Jonathan Messika
European Respiratory Journal Sep 2015, 46 (3) 876-877; DOI: 10.1183/09031936.00048715

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Nonsteroidal anti-inflammatory drugs in community-acquired pneumonia
Jean-Damien Ricard, Jonathan Messika
European Respiratory Journal Sep 2015, 46 (3) 876-877; DOI: 10.1183/09031936.00048715
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Respiratory infections and tuberculosis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • NTM-PD incidence among elderly patients with bronchiectasis
  • Inaccuracy of pulse oximetry in darker skinned patients unchanged across 32 years
  • Reply: Inaccuracy of pulse oximetry in darker skinned patients unchanged across 32 years
Show more Agora

Correspondence

  • Inaccuracy of pulse oximetry in darker skinned patients unchanged across 32 years
  • Reply: Inaccuracy of pulse oximetry in darker skinned patients unchanged across 32 years
  • Radiomics in ILD associated with systemic sclerosis
Show more Correspondence

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society